The FDA has approved the first non-antipsychotic medication for treating agitation in patients with Alzheimer's disease, marking a significant shift in the pharmacological management of dementia-related behavioral symptoms.
A single dose of psilocybin produces measurable positive changes in brain activity, providing mechanistic insight into its potential therapeutic effects for psychiatric conditions.
rTMS stimulation of the dorsolateral prefrontal cortex significantly reduces cigarette consumption, offering a non-pharmacologic precision-medicine option for smoking cessation.
The Minnesota House has approved a psilocybin therapy program within the state budget bill, marking a significant legislative step for the regulation and clinical implementation of this psychedelic treatment.
A UAB study indicates psilocybin shows promise as a treatment for cocaine use disorder, highlighting potential off-label or investigational applications of psychedelics in substance use disorder.
Clinical Pearls
Bite-sized clinical takeaways from today's literature (sources from Mar 09 – May 09)
- Utilize lumateperone for relapse prevention in schizophrenia, leveraging its favorable metabolic and prolactin profile compared to other atypical antipsychotics.
- Consider genotype-guided SSRI selection to significantly increase depression remission rates at six months in treatment-resistant or complex cases.
- Monitor QTc intervals and perform CYP2D6 genotyping when considering ibogaine for opioid or cocaine dependence due to risks of fatal ventricular arrhythmias.
- Counsel pregnant patients with opioid use disorder that buprenorphine may have lower retention rates than methadone, necessitating enhanced supportive care strategies.
- Offer rTMS to the dorsolateral prefrontal cortex as a non-pharmacologic precision-medicine option for smoking cessation in patients seeking to reduce cigarette consumption.
- Prescribe lumateperone with awareness of its expanded indication for schizophrenia relapse prevention, supported by data showing a 63% reduction in relapse risk over 6 to 12 months.
- Recognize that a single dose of psilocybin induces measurable brain connectivity changes lasting up to a month, informing the rationale for its investigational use in substance use disorders.
- Monitor for cardiovascular safety and consider CYP2D6 status when evaluating off-label or investigational use of ibogaine for stimulant or opioid dependence.
- Acknowledge the significant shift in adult stimulant prescribing patterns post-pandemic when reviewing new or existing ADHD medication regimens.
- Stay informed on emerging FDA and state-level legislative changes regarding psychedelic therapies, particularly psilocybin for cocaine use disorder and Alzheimer's agitation protocols.
Policy & Regulation 3
The Minnesota House has approved legislation to legalize psychedelic mushrooms for therapeutic use, representing a significant state-level policy shift in the regulation of psychedelics.
President Trump's executive order accelerates psychedelic drug development and approval through FDA priority vouchers, DEA scheduling reforms, and ARPA-H funding, raising questions about clinical readiness.
The FDA has approved lumateperone for the prevention of relapse in schizophrenia, expanding its therapeutic indication for this atypical antipsychotic.
Mechanism of Action 2
Research indicates that a single dose of psilocybin may provide weeks of relief by reshaping brain connectivity, highlighting a potential mechanism for its therapeutic effects in psychiatric conditions.
A single dose of psilocybin induces brain changes lasting up to a month, providing mechanistic insight into the prolonged effects of this psychedelic treatment.
Substance Use 3
Emerging data suggests psilocybin may be a promising treatment for cocaine use disorder, highlighting potential off-label or investigational use of a psychedelic compound in substance use disorder.
This retrospective cohort study highlights lower retention rates for buprenorphine compared to methadone in pregnant women with opioid use disorder, underscoring the need for targeted support as guidelines shift toward buprenorphine as first-line therapy.
Ibogaine, a psychedelic alkaloid with anti-addictive potential for opioid and cocaine dependence, carries a significant risk of QTc prolongation and fatal ventricular arrhythmias, necessitating cardiovascular monitoring and CYP2D6 genotyping in clinical settings.
Neuroscience 1
New evidence confirms psilocybin alters brain function after a single dose and identifies traditional use outside the Americas, supporting its potential as a psychiatric therapeutic agent.
Drug Development 1
Pharmacogenomics 1
A genotype-guided SSRI prescription strategy significantly increased depression remission rates at six months, highlighting the clinical utility of pharmacogenomics in optimizing antidepressant selection.